The Recovery Enhancement for Addiction Treatment Act
or TREAT Act
Introduced on 5-21-15 by Brian Higgins [D-NY-26]. Cosponsors were Richard Hanna [R-NY-22], Paul Tonko [D-NY-20], John Katko [R-NY-24], Steve Cohen [D-TN-9], Christopher Gibson [R-NY-19], Elise Stefanik [R-NY-21], Katherine Clark [D-MA-5], Earl Blumenauer [D-OR-3], Peter Welch [D-VT-At Large], Tim Ryan [D-OH-13], Alcee Hastings [D-FL-20], Ben Ray Lujan [D-NM-3], David McKinley [R-WV-1], Elizabeth Esty [D-CT-5], Ruben Gallego [D-AZ-7], Tammy Duckworth [D-IL-8], Chellie Pingree [D-ME-1], Eric Swalwell [ D-CA-15], Sheila Jackson Lee [D-TX-18], Mark DeSaulnier [D-CA-11], Frank Guinta [R-NH-1], Ann Kuster [D-NH-2], Bill Foster [D-IL-11], Lou Barletta [R-PA-11], Seth Moulton [D-MA-6], and Marcy Kaptur [D-OH-9]. Related bills are H.R.4396, H.R.4435, S.1455 (Identical Bill), and S.256
Purpose: To provide access to medication-assisted therapy, and for other purposes.
SEC. 2. Findings.
Congress finds the following:
(1) Overdoses from opioids have increased dramatically in the United States, deaths from drug overdose have tripled among men and increased five-fold among women over the past decade. Nationwide, drug overdoses now claim more lives than car accidents.
(2)Opioid addiction is a chronic disease that, untreated, places a large burden on the healthcare system. Effective medication-assisted treatment for opioid addiction, in combination with counseling and behavioral therapies, can decrease overdose deaths, be cost-effective, reduce transmissions of HIV and viral hepatitis, and reduce other social harms such as criminal activity. These programs should include medications, cognitive and behavioral supports and drug testing. Access to these programs remains limited due to practice regulations and an insufficient number of providers.
SEC. 3. Expansion of patient limits under waiver.
Increases practitioners to include nurse practitioners and physician assistants. Increases the number of patients allowed per practitioner to 500 after one year of experience in the program.
Two years after this Act takes effect, the Secretary of HHS shall evaluate the effectiveness of it as to availability of medication-assisted treatment, the quality and integration of these programs into routine healthcare services, diversion of the treatment medication and changes in State or local policies.